| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 9704 | Y-DOTA-TOC |
Please inquire for customized filling and bulk quantities.
|
|
Reference Standard for 90Y-DOTA-TOC
|
||
| Molar Mass: 1507.52 (net peptide) | ||
| C65H89N14O18S2Y | ||
| [293295-66-6] | ||
| Colourless to off-white solid packaged in dark glass screw cap vials. | ||
| Purity: ≥ 95 % | ||
|
Certificates:
CoA; MS (identity); HPLC (purity) |
||
|
Chemical Name: Sequence: DOTA(Y)-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide. |
||
|
Synonymes: natY-Edotreotide; natY-SMT487; natY-DOTA-[Tyr3]octreotide; Yttrium, [N-[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2→7)-disulfidato(3-)]- |
||
|
Literature: Villard L. et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 2012, 30, 1100-1106. |
||
| date of product catalogue issue: 10 May 2017 | ||